vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Tyler Technologies (TYL). Click either name above to swap in a different company.

Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $613.5M, roughly 1.2× Tyler Technologies). Tyler Technologies runs the higher net margin — 13.2% vs 10.8%, a 2.4% gap on every dollar of revenue. On growth, Tyler Technologies posted the faster year-over-year revenue change (8.6% vs 3.9%). Over the past eight quarters, Tyler Technologies's revenue compounded faster (6.5% CAGR vs 1.5%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

Tyler Technologies, Inc. is an American technology company based in Plano, Texas, that provides proprietary software to the U.S. public sector. Tyler Technologies has offices in 17 states and one in Toronto, Ontario, Canada.

AMRX vs TYL — Head-to-Head

Bigger by revenue
AMRX
AMRX
1.2× larger
AMRX
$722.5M
$613.5M
TYL
Growing faster (revenue YoY)
TYL
TYL
+4.7% gap
TYL
8.6%
3.9%
AMRX
Higher net margin
TYL
TYL
2.4% more per $
TYL
13.2%
10.8%
AMRX
Faster 2-yr revenue CAGR
TYL
TYL
Annualised
TYL
6.5%
1.5%
AMRX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AMRX
AMRX
TYL
TYL
Revenue
$722.5M
$613.5M
Net Profit
$78.0M
$81.2M
Gross Margin
44.3%
48.3%
Operating Margin
19.6%
16.3%
Net Margin
10.8%
13.2%
Revenue YoY
3.9%
8.6%
Net Profit YoY
410.5%
EPS (diluted)
$0.19
$1.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
TYL
TYL
Q1 26
$722.5M
$613.5M
Q4 25
$814.3M
$575.2M
Q3 25
$784.5M
$595.9M
Q2 25
$724.5M
$596.1M
Q1 25
$695.4M
$565.2M
Q4 24
$730.5M
$541.1M
Q3 24
$702.5M
$543.3M
Q2 24
$701.8M
$541.0M
Net Profit
AMRX
AMRX
TYL
TYL
Q1 26
$78.0M
$81.2M
Q4 25
$35.1M
$65.5M
Q3 25
$2.4M
$84.4M
Q2 25
$22.4M
$84.6M
Q1 25
$12.2M
$81.1M
Q4 24
$-31.1M
$65.2M
Q3 24
$-156.0K
$75.9M
Q2 24
$6.0M
$67.7M
Gross Margin
AMRX
AMRX
TYL
TYL
Q1 26
44.3%
48.3%
Q4 25
36.5%
45.5%
Q3 25
34.9%
47.2%
Q2 25
39.5%
45.8%
Q1 25
36.8%
47.3%
Q4 24
36.0%
43.8%
Q3 24
38.4%
43.7%
Q2 24
35.6%
44.0%
Operating Margin
AMRX
AMRX
TYL
TYL
Q1 26
19.6%
16.3%
Q4 25
13.8%
13.0%
Q3 25
9.0%
16.4%
Q2 25
15.4%
16.0%
Q1 25
14.4%
15.8%
Q4 24
10.4%
13.2%
Q3 24
12.6%
15.2%
Q2 24
13.6%
14.4%
Net Margin
AMRX
AMRX
TYL
TYL
Q1 26
10.8%
13.2%
Q4 25
4.3%
11.4%
Q3 25
0.3%
14.2%
Q2 25
3.1%
14.2%
Q1 25
1.8%
14.3%
Q4 24
-4.3%
12.1%
Q3 24
-0.0%
14.0%
Q2 24
0.9%
12.5%
EPS (diluted)
AMRX
AMRX
TYL
TYL
Q1 26
$0.19
$1.88
Q4 25
$0.10
$1.50
Q3 25
$0.01
$1.93
Q2 25
$0.07
$1.93
Q1 25
$0.04
$1.84
Q4 24
$-0.10
$1.48
Q3 24
$0.00
$1.74
Q2 24
$0.02
$1.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
TYL
TYL
Cash + ST InvestmentsLiquidity on hand
$197.7M
$346.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$3.6B
Total Assets
$3.5B
$4.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
TYL
TYL
Q1 26
$197.7M
$346.4M
Q4 25
$282.0M
$1.1B
Q3 25
$201.2M
$950.8M
Q2 25
$71.5M
$892.3M
Q1 25
$59.2M
$807.4M
Q4 24
$110.6M
$768.0M
Q3 24
$74.0M
$544.3M
Q2 24
$43.8M
$258.0M
Total Debt
AMRX
AMRX
TYL
TYL
Q1 26
Q4 25
$2.6B
$599.7M
Q3 25
$2.6B
$599.2M
Q2 25
$2.2B
$598.8M
Q1 25
$2.2B
$598.4M
Q4 24
$2.4B
$597.9M
Q3 24
$2.4B
$597.5M
Q2 24
$2.4B
$597.1M
Stockholders' Equity
AMRX
AMRX
TYL
TYL
Q1 26
$3.6B
Q4 25
$-70.8M
$3.7B
Q3 25
$-109.5M
$3.6B
Q2 25
$-112.1M
$3.6B
Q1 25
$-131.7M
$3.5B
Q4 24
$-109.3M
$3.4B
Q3 24
$-93.4M
$3.3B
Q2 24
$-57.5M
$3.1B
Total Assets
AMRX
AMRX
TYL
TYL
Q1 26
$3.5B
$4.8B
Q4 25
$3.7B
$5.6B
Q3 25
$3.6B
$5.5B
Q2 25
$3.4B
$5.4B
Q1 25
$3.4B
$5.2B
Q4 24
$3.5B
$5.2B
Q3 24
$3.5B
$5.0B
Q2 24
$3.5B
$4.8B
Debt / Equity
AMRX
AMRX
TYL
TYL
Q1 26
Q4 25
0.16×
Q3 25
0.17×
Q2 25
0.16×
Q1 25
0.17×
Q4 24
0.18×
Q3 24
0.18×
Q2 24
0.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
TYL
TYL
Operating Cash FlowLast quarter
$107.3M
Free Cash FlowOCF − Capex
$2.0M
FCF MarginFCF / Revenue
0.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.32×
TTM Free Cash FlowTrailing 4 quarters
$585.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
TYL
TYL
Q1 26
$107.3M
Q4 25
$130.3M
$243.9M
Q3 25
$118.5M
$255.2M
Q2 25
$83.8M
$98.3M
Q1 25
$7.4M
$56.2M
Q4 24
$118.1M
$224.8M
Q3 24
$141.8M
$263.7M
Q2 24
$39.7M
$64.3M
Free Cash Flow
AMRX
AMRX
TYL
TYL
Q1 26
$2.0M
Q4 25
$108.5M
$239.6M
Q3 25
$106.2M
$251.3M
Q2 25
$61.0M
$92.8M
Q1 25
$-5.8M
$53.8M
Q4 24
$102.9M
$221.0M
Q3 24
$124.8M
$260.8M
Q2 24
$29.0M
$57.7M
FCF Margin
AMRX
AMRX
TYL
TYL
Q1 26
0.3%
Q4 25
13.3%
41.7%
Q3 25
13.5%
42.2%
Q2 25
8.4%
15.6%
Q1 25
-0.8%
9.5%
Q4 24
14.1%
40.8%
Q3 24
17.8%
48.0%
Q2 24
4.1%
10.7%
Capex Intensity
AMRX
AMRX
TYL
TYL
Q1 26
Q4 25
2.7%
0.8%
Q3 25
1.6%
0.7%
Q2 25
3.2%
0.9%
Q1 25
1.9%
0.4%
Q4 24
2.1%
0.7%
Q3 24
2.4%
0.5%
Q2 24
1.5%
1.2%
Cash Conversion
AMRX
AMRX
TYL
TYL
Q1 26
1.32×
Q4 25
3.72×
3.72×
Q3 25
50.00×
3.02×
Q2 25
3.74×
1.16×
Q1 25
0.61×
0.69×
Q4 24
3.45×
Q3 24
3.47×
Q2 24
6.62×
0.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRX
AMRX

Segment breakdown not available.

TYL
TYL

Subscriptions$429.7M70%
Maintenance$108.9M18%
Other$74.9M12%

Related Comparisons